GO:0004060 arylamine N-acetyltransferase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004060 arylamine N-acetyltransferase activity catalyzes the acetyl-CoA-dependent N-acetylation of arylamine substrates, producing CoA and an N-acetylarylamine.
• In humans, this activity is carried out mainly by NAT1 and NAT2, which show distinct substrate specificities and tissue expression patterns.
• NAT1 and NAT2 are highly polymorphic, and genetic variants influence enzyme activity, drug metabolism, and cancer susceptibility.
• Arylamine N-acetyltransferase activity is not limited to humans; it has been detected in bacteria such as Escherichia coli and Helicobacter pylori.
• Altered NAT1 expression and activity have been reported in childhood acute lymphoblastic leukemia and in cancer cell metabolism.
• CRISPR-based knockout, point-mutation, knock-in, and overexpression models enable causal dissection of NAT1/NAT2 function in disease and drug response.
Description
Arylamine N-acetyltransferase activity (GO:0004060) is a molecular function defined by the acetyl-CoA-dependent acetylation of arylamine substrates to form CoA and an N-acetylarylamine. This activity is central to the phase II metabolism of many xenobiotics, including aromatic amines, hydrazines, and drugs such as isoniazid and sulfonamides. In humans, the enzymes NAT1 and NAT2 are the principal carriers of this activity, and their genetic polymorphisms are among the most extensively studied determinants of interindividual variability in drug response and carcinogen activation. Beyond drug metabolism, arylamine N-acetyltransferase activity has been detected in bacteria, where it may contribute to xenobiotic transformation and host-microbe interactions. Recent work has also linked NAT1 expression to cancer cell metabolism, including glucose dependence and mitochondrial bioenergetics, and to childhood acute lymphoblastic leukemia. Because of its broad substrate range and clinical relevance, GO:0004060 remains a focus for pharmacogenomics, toxicology, and cancer biology research.
arylamine N-acetyltransferase activity At A Glance
| GO ID | GO:0004060 |
|---|---|
| GO term | arylamine N-acetyltransferase activity |
| Ontology | molecular_function |
| Definition | Catalysis of the reaction: acetyl-CoA + an arylamine = CoA + an N-acetylarylamine. |
| Synonym | 2-naphthylamine N-acetyltransferase activity; 4-aminobiphenyl N-acetyltransferase activity; acetyl CoA-arylamine N-acetyltransferase activity; acetyl-CoA:arylamine N-acetyltransferase activity; arylamine acetylase activity; arylamine acetyltransferase activity; beta-naphthylamine N-acetyltransferase activity; indoleamine N-acetyltransferase activity; p-aminosalicylate N-acetyltransferase activity |
| Major function | Acetyl-CoA-dependent N-acetylation of arylamine substrates, including drugs and environmental carcinogens. |
| Representative human genes | NAT1 and NAT2. |
| Subcellular context | Cytosolic phase II drug-metabolizing enzymes in humans. |
| Clinical relevance | Polymorphisms affect drug metabolism, carcinogen activation, and cancer risk. |
What Is GO:0004060?
Arylamine N-acetyltransferase activity (GO:0004060) is the catalysis of the reaction acetyl-CoA + an arylamine = CoA + an N-acetylarylamine. In other words, it transfers an acetyl group from acetyl-CoA to the nitrogen of an arylamine substrate, yielding a CoA molecule and an N-acetylated arylamine product. This activity is synonymous with arylamine acetylase, arylamine acetyltransferase, and acetyl-CoA:arylamine N-acetyltransferase activity, and it includes historically named activities such as 2-naphthylamine N-acetyltransferase, 4-aminobiphenyl N-acetyltransferase, indoleamine N-acetyltransferase, and p-aminosalicylate N-acetyltransferase.
Why Is arylamine N-acetyltransferase activity Important in Cell Biology?
Arylamine N-acetyltransferase activity is important because it governs the metabolic fate of numerous drugs and environmental chemicals, and its genetic variability is a classic example of pharmacogenetic polymorphism. NAT1 and NAT2 acetylation can either detoxify or bioactivate arylamine carcinogens, thereby modulating cancer risk. The activity has also been found in bacteria, suggesting roles in microbial xenobiotic metabolism and host-microbe interactions. More recently, NAT1 expression has been linked to cancer cell metabolic reprogramming and to childhood acute lymphoblastic leukemia, expanding its relevance beyond drug metabolism. Understanding GO:0004060 therefore informs pharmacology, toxicology, oncology, and microbiome research.
• Determines the pharmacokinetics of arylamine-containing drugs such as isoniazid and sulfonamides.
• Modulates activation or detoxification of aromatic amine carcinogens, influencing cancer susceptibility.
• NAT1 and NAT2 polymorphisms are among the most studied pharmacogenetic variants in humans.
• Bacterial arylamine N-acetyltransferase activity may affect xenobiotic transformation in the gut.
• NAT1 expression has been associated with glucose dependence and mitochondrial bioenergetics in cancer cells.
• Altered NAT1 and miR-1290 levels have been reported in childhood acute lymphoblastic leukemia.
• Provides a model system for studying gene-environment interactions in toxicology.
• Supports development of CRISPR models to test causal roles of NAT1/NAT2 variants.
• Relevant to personalized medicine and dosing of acetylated drugs.
• Contributes to understanding of phase II metabolism beyond glucuronidation and sulfation.
Molecular Mechanism of arylamine N-acetyltransferase activity
Substrate binding and acetyl-CoA utilization
In simple terms: The enzyme grabs an acetyl group from acetyl-CoA and hands it to an arylamine molecule.
Arylamine N-acetyltransferase activity uses acetyl-CoA as the acetyl donor and an arylamine as the acceptor substrate. The reaction yields CoA and an N-acetylarylamine product, and the activity is defined by this acetyl transfer chemistry. Substrate specificity varies among enzymes carrying this activity; for example, human NAT1 and NAT2 differ in their preferred arylamine substrates.
Catalytic mechanism and enzyme classes
In simple terms: Different enzymes can perform the same acetylation reaction, but they may prefer different targets.
The catalytic mechanism involves nucleophilic attack of the arylamine nitrogen on the acetyl group of acetyl-CoA, forming an acetyl-enzyme intermediate or a direct transfer depending on the enzyme. In humans, NAT1 and NAT2 are the major enzymes annotated with GO:0004060, and their activity can be regulated by genetic and non-genetic factors. Bacterial enzymes such as those from Escherichia coli and Helicobacter pylori also display arylamine N-acetyltransferase activity, indicating evolutionary conservation of this function.
Genetic polymorphisms and activity variation
In simple terms: Small changes in the NAT1 or NAT2 gene can change how fast a person acetylates drugs.
NAT1 and NAT2 are highly polymorphic, and these variants can alter enzyme activity, leading to rapid, intermediate, or slow acetylator phenotypes. Polymorphisms in the NAT1 3'-untranslated region can affect polyadenylation signal usage and thus transcript stability or expression. Such genetic variation is a major source of interindividual differences in drug metabolism and carcinogen handling.
Regulation by non-genetic factors
In simple terms: Diet, environment, and other non-genetic factors can also influence how active the enzyme is.
Beyond genetic polymorphisms, non-genetic factors such as substrate availability, cofactor levels, and cellular environment can regulate arylamine N-acetyltransferase activity. The activity is also subject to post-transcriptional regulation, as shown by the role of miR-1290 in childhood acute lymphoblastic leukemia. In cancer cells, NAT1 expression has been linked to metabolic state, including glucose dependence and mitochondrial bioenergetics.
Bacterial and non-human arylamine N-acetyltransferase activity
In simple terms: Bacteria also have enzymes that perform this acetylation reaction.
Arylamine N-acetyltransferase activity has been detected in Escherichia coli and Helicobacter pylori, suggesting that bacteria can acetylate arylamine substrates. This bacterial activity may contribute to xenobiotic metabolism in the host and could influence drug efficacy or toxicity. Comparative studies of bacterial and human enzymes can reveal conserved catalytic features and differences in substrate range.
Key Genes Involved in GO:0004060 arylamine N-acetyltransferase activity
The following genes and proteins are directly associated with arylamine N-acetyltransferase activity (GO:0004060) or its regulation in humans and bacteria.
| Gene | Major Role | Research Relevance |
|---|---|---|
| NAT1 | Major human arylamine N-acetyltransferase; acetylates p-aminosalicylate and other substrates | Polymorphisms affect drug metabolism and cancer risk; linked to leukemia and cancer metabolism |
| NAT2 | Major human arylamine N-acetyltransferase; acetylates isoniazid, sulfonamides, and carcinogens | Classic pharmacogenetic gene; rapid/slow acetylator phenotypes |
| NAT1 3'UTR variants | Regulate polyadenylation signal usage and transcript processing | Functional impact on NAT1 expression and activity |
| miR-1290 | Post-transcriptional regulator associated with NAT1 levels in leukemia | Potential biomarker or therapeutic target in childhood ALL |
| RIPK1 | Substrate for acetylhypusination by spermidine, not directly NAT1/NAT2 | Context for acetylation-related signaling in diabetes |
| E. coli arylamine N-acetyltransferase | Bacterial enzyme with arylamine N-acetyltransferase activity | Model for microbial xenobiotic metabolism |
| H. pylori arylamine N-acetyltransferase | Bacterial enzyme with arylamine N-acetyltransferase activity | Potential role in gastric carcinogenesis and drug metabolism |
| Acetyl-CoA | Cofactor and acetyl donor for the reaction | Central metabolite linking metabolism to acetylation |
| CoA | Product of the reaction | Marker of acetyl transfer |
| N-acetylarylamine | Product of the reaction | Measured to quantify enzyme activity |
| Arylamine substrates | Acceptors for acetylation, including drugs and carcinogens | Determine substrate specificity and biological outcome |
| NAT1/NAT2 genetic variants | Alter enzyme activity and acetylator status | Pharmacogenomic testing and personalized medicine |
| Glucose metabolism pathways | Linked to NAT1 expression in cancer cells | Metabolic targeting in cancer research |
| Mitochondrial bioenergetics | Associated with NAT1 expression | Cancer cell metabolism studies |
| Childhood ALL pathways | NAT1 and miR-1290 alterations reported | Pediatric leukemia research |
| Spermidine/acetylhypusination pathway | Acetylation-related modification of RIPK1 | Diabetes and cell death research |
| Phase II drug metabolism network | Includes NAT1/NAT2 alongside other conjugating enzymes | Toxicology and drug development |
| Xenobiotic response pathways | Arylamine acetylation as a detoxification/bioactivation step | Environmental health and carcinogenesis |
How Is arylamine N-acetyltransferase activity Regulated?
Arylamine N-acetyltransferase activity is regulated at multiple levels. Genetic polymorphisms in NAT1 and NAT2 are major determinants of enzyme activity, producing rapid, intermediate, and slow acetylator phenotypes. In addition, non-genetic factors such as substrate availability, cofactor levels, and cellular environment can modulate activity. Post-transcriptional regulation has been demonstrated for NAT1, including 3'-untranslated region polymorphisms that affect polyadenylation signal usage and regulation by miR-1290 in childhood acute lymphoblastic leukemia. In cancer cells, NAT1 expression has been associated with glucose dependence and mitochondrial bioenergetics, suggesting metabolic regulation. Acetylation-related signaling, such as acetylhypusination of RIPK1 by spermidine, provides a broader context for acetylation in cell fate and disease.
arylamine N-acetyltransferase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| NAT1 | Childhood acute lymphoblastic leukemia; cancer metabolism | NAT1 knockout and overexpression in leukemia cell lines |
| NAT2 | Drug toxicity and cancer susceptibility | NAT2 point-mutation models for slow/rapid acetylator phenotypes |
| NAT1 3'UTR | Altered polyadenylation and expression | Knock-in of 3'UTR variants to study transcript processing |
| Bacterial NAT | Xenobiotic metabolism in E. coli and H. pylori | Bacterial knockout and complementation models |
| RIPK1 (acetylation context) | Diabetes onset and progression | Acetylation-site knock-in or knockout models |
Cancer and carcinogen metabolism
Arylamine N-acetyltransferase activity is implicated in cancer because NAT1 and NAT2 can activate or detoxify aromatic amine carcinogens. Genetic polymorphisms that alter enzyme activity are associated with altered cancer susceptibility, although the direction of effect depends on the specific carcinogen and tissue. In childhood acute lymphoblastic leukemia, altered NAT1 and miR-1290 levels have been reported, suggesting a role in leukemogenesis or disease progression. NAT1 expression has also been linked to glucose dependence and mitochondrial bioenergetics in cancer cells, indicating a metabolic dimension to its role in tumors.
Drug metabolism and pharmacogenetics
NAT2 acetylation is a classic pharmacogenetic trait affecting drugs such as isoniazid, sulfonamides, and hydralazine. Slow acetylators may be at higher risk of drug toxicity, while rapid acetylators may have reduced efficacy for some prodrugs. NAT1 also contributes to drug and xenobiotic metabolism, and its polymorphisms can influence substrate handling. These relationships make arylamine N-acetyltransferase activity a key consideration in personalized medicine and drug development.
Bacterial infections and microbiome
Arylamine N-acetyltransferase activity has been detected in Escherichia coli and Helicobacter pylori, suggesting that bacteria can acetylate arylamine substrates in the host environment. This bacterial activity may influence the metabolism of drugs or carcinogens in the gut and could contribute to H. pylori-associated gastric disease. Studying bacterial arylamine N-acetyltransferase activity may reveal new targets for modulating host-microbe interactions.
Metabolic and acetylation-related disorders
Acetylation pathways beyond NAT1/NAT2, such as acetylhypusination of RIPK1 by spermidine, have been linked to diabetes onset and progression. Although this specific modification is not directly mediated by arylamine N-acetyltransferase activity, it highlights the broader importance of acetylation in metabolic disease. NAT1 expression has also been associated with glucose dependence in cancer cells, suggesting a potential connection between arylamine acetylation and cellular metabolism.
From arylamine N-acetyltransferase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does NAT1 loss alter drug sensitivity? | NAT1 knockout cell lines |
| Does a NAT2 polymorphism change acetylation rate? | NAT2 point-mutation knock-in cells |
| Does NAT1 overexpression affect cancer metabolism? | NAT1 overexpression in cancer cell lines |
| Does a 3'UTR variant alter NAT1 transcript stability? | Knock-in of NAT1 3'UTR variants |
| Does bacterial NAT activity affect host cells? | Bacterial NAT knockout and co-culture models |
| Does miR-1290 regulate NAT1 in leukemia? | miR-1290 mimic/inhibitor and NAT1 reporter models |
How to Study the arylamine N-acetyltransferase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Colorimetric NAT assay | N-acetylarylamine formation | Comparing acetylator phenotypes in cells or lysates |
| HPLC/LC-MS | Substrate and product quantification | Drug metabolism and carcinogen activation studies |
| Genotyping (PCR/sequencing) | NAT1/NAT2 polymorphisms | Pharmacogenetic classification |
| qRT-PCR | NAT1/NAT2 mRNA levels | Expression analysis in disease models |
| Western blot | NAT1/NAT2 protein levels | Validation of expression changes |
| Reporter assay | Regulatory activity of 3'UTR or promoters | Studying polyadenylation and miRNA regulation |
| CRISPR knockout | Loss-of-function effects | Causal testing of NAT1/NAT2 function |
| CRISPR knock-in | Variant-specific effects | Modeling polymorphisms and 3'UTR variants |
Enzyme activity assays
Arylamine N-acetyltransferase activity can be measured using colorimetric or chromatographic assays that detect the formation of N-acetylarylamine products or the consumption of acetyl-CoA. These assays are used to compare activity between genotypes, tissues, or cell lines and to determine acetylator phenotypes. Bacterial lysates can also be assayed to detect arylamine N-acetyltransferase activity in microorganisms.
Genotyping and polymorphism analysis
PCR-based genotyping, sequencing, and allele-specific assays are used to identify NAT1 and NAT2 polymorphisms that affect enzyme activity. These methods help classify individuals or cell lines as rapid, intermediate, or slow acetylators. Analysis of the NAT1 3'-untranslated region can reveal variants that alter polyadenylation signal usage.
Expression and regulatory studies
Quantitative RT-PCR, western blotting, and reporter assays are used to measure NAT1/NAT2 expression and to study regulatory mechanisms. MicroRNA studies, such as those examining miR-1290, can identify post-transcriptional regulators of NAT1. Metabolic assays can link NAT1 expression to glucose dependence and mitochondrial function.
CRISPR-based functional genomics
CRISPR knockout, point-mutation, knock-in, and overexpression models allow causal testing of NAT1/NAT2 variants and regulatory elements. These models can be combined with activity assays, transcriptomics, and metabolomics to dissect the consequences of altered arylamine N-acetyltransferase activity. Library screening and bioinformatics can identify modifiers of acetylation phenotypes.
How CRISPR Can Be Used to Study GO:0004060 arylamine N-acetyltransferase activity
Knockout
CRISPR knockout of NAT1 or NAT2 can abolish arylamine N-acetyltransferase activity in cell models, enabling studies of drug sensitivity, carcinogen metabolism, and metabolic reprogramming. Knockout models are useful for determining whether a specific acetylation event is required for a phenotype. They can also be used to validate bacterial NAT functions in E. coli or H. pylori.
Point Mutation
CRISPR point-mutation models can introduce specific NAT1 or NAT2 polymorphisms to mimic rapid, intermediate, or slow acetylator genotypes. These models allow precise testing of how single-nucleotide variants affect enzyme activity and downstream drug or carcinogen responses. Point mutations in the NAT1 3'UTR can also be generated to study polyadenylation signal usage.
Knock-in
Knock-in models can replace endogenous NAT1 or NAT2 alleles with variant sequences or tags to study expression, localization, and regulation. Tagged knock-in of NAT1 can facilitate protein interaction and stability studies. Knock-in of 3'UTR variants can reveal effects on transcript processing and miRNA binding.
Overexpression
Overexpression of NAT1 or NAT2 in cell lines can model high-activity states and test whether increased acetylation alters cancer metabolism, drug response, or stress pathways. Overexpression models are also useful for studying substrate specificity and enzyme kinetics. Combined with metabolic assays, they can link arylamine N-acetyltransferase activity to glucose dependence and mitochondrial bioenergetics.
How EDITGENE Supports arylamine N-acetyltransferase activity Research
Researchers studying arylamine N-acetyltransferase activity-related genes often need to determine whether a candidate gene is causally involved in drug metabolism, carcinogen activation, or cancer phenotypes. EDITGENE provides CRISPR-based cell model services that enable precise manipulation of NAT1, NAT2, and related regulatory elements, helping teams move from association to mechanism.
Contact EDITGENE today to design your custom CRISPR model for arylamine N-acetyltransferase activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| NAT1 Knockout HEK293 Cell Line | EDJ-KQ2341 | Human | 9 | Details Get a Quote |
| NAT2 Knockout HEK293 Cell Line | EDJ-KQ2435 | Human | 10 | Details Get a Quote |
| AANAT Knockout HEK293 Cell Line | EDJ-KQ3987 | Human | 15 | Details Get a Quote |
| NAT1 Knockout A-549 Cell Line | EDJ-KQ22758 | Human | 9 | Details Get a Quote |
| NAT1 Knockout HCT 116 Cell Line | EDJ-KQ22759 | Human | 9 | Details Get a Quote |
| NAT1 Knockout HeLa Cell Line | EDJ-KQ22760 | Human | 9 | Details Get a Quote |
| NAT2 Knockout HeLa Cell Line | EDJ-KQ52528 | Human | 10 | Details Get a Quote |
| AANAT Knockout HeLa Cell Line | EDJ-KQ52531 | Human | 15 | Details Get a Quote |
| NAT2 Knockout A-549 Cell Line | EDJ-KQ61011 | Human | 10 | Details Get a Quote |
| AANAT Knockout A-549 Cell Line | EDJ-KQ61012 | Human | 15 | Details Get a Quote |
| NAT2 Knockout HCT 116 Cell Line | EDJ-KQ69484 | Human | 10 | Details Get a Quote |
| AANAT Knockout HCT 116 Cell Line | EDJ-KQ69486 | Human | 15 | Details Get a Quote |
Displaying Records 1 To 12 Of 12 Records
Frequently Asked Questions About arylamine N-acetyltransferase activity
What is arylamine N-acetyltransferase activity?
It is the acetyl-CoA-dependent acetylation of arylamine substrates to form CoA and an N-acetylarylamine, annotated as GO:0004060.
What genes are involved in arylamine N-acetyltransferase activity?
In humans, NAT1 and NAT2 are the major genes; bacterial enzymes from E. coli and H. pylori also carry this activity.
What is the GO ID for arylamine N-acetyltransferase activity?
The Gene Ontology ID is GO:0004060.
What is the reaction catalyzed by arylamine N-acetyltransferase?
Acetyl-CoA + an arylamine = CoA + an N-acetylarylamine.
How do NAT1 and NAT2 polymorphisms affect drug metabolism?
They alter enzyme activity and produce rapid, intermediate, or slow acetylator phenotypes, affecting drugs like isoniazid and sulfonamides.
Is arylamine N-acetyltransferase activity found in bacteria?
Yes, it has been detected in Escherichia coli and Helicobacter pylori.
How is arylamine N-acetyltransferase activity measured?
Common methods include colorimetric assays, HPLC/LC-MS, and genotyping to infer acetylator status.
What diseases are linked to arylamine N-acetyltransferase activity?
Cancer susceptibility, drug toxicity, childhood acute lymphoblastic leukemia, and metabolic conditions have been associated with NAT1/NAT2 or related acetylation pathways.
Can CRISPR be used to study arylamine N-acetyltransferase activity?
Yes, CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal studies of NAT1/NAT2 function.
What is the role of NAT1 in cancer metabolism?
NAT1 expression has been linked to glucose dependence and mitochondrial bioenergetics in cancer cells.
Conclusion
Arylamine N-acetyltransferase activity (GO:0004060) is a fundamental phase II metabolic function with broad implications for drug metabolism, carcinogen activation, and cancer biology. The human NAT1 and NAT2 enzymes, their polymorphisms, and their regulatory mechanisms are central to pharmacogenomics and disease risk assessment. Bacterial arylamine N-acetyltransferase activity further expands the biological scope of this function. CRISPR-based models now provide powerful tools to move from association to causation in NAT1/NAT2 research. Continued investigation of GO:0004060 will inform personalized medicine, toxicology, and cancer therapeutics.
References
- 1. Cascorbi I et al.. 1999. Arylamine N-acetyltransferase activity in man.. Drug Metab Rev 31(2):489-502 PMID: 10335449
- 2. Rodrigues-Lima F et al.. 2004. Regulation of the activity of the human drug metabolizing enzyme arylamine N-acetyltransferase 1: role of genetic and non genetic factors.. Curr Pharm Des 10(20):2519-24 PMID: 15320760
- 3. Chang FC et al.. 1998. Evidence for arylamine N-acetyltransferase activity in the Escherichia coli.. Curr Microbiol 36(3):125-30 PMID: 9516539
- 4. Chung JG et al.. 1997. Evidence for arylamine N-acetyltransferase activity in the bacterium Helicobacter pylori.. Toxicol Lett 91(1):63-71 PMID: 9096288
- 5. Hernandez-Gonzalez O et al.. 2023. Altered Arylamine N-acetyltransferase 1 and miR-1290 Levels in Childhood Acute Lymphoblastic Leukemia: A Pilot Study.. In Vivo 37(3):1129-1144 PMID: 37103073
- 6. Zhang T et al.. 2024. Spermidine mediates acetylhypusination of RIPK1 to suppress diabetes onset and progression.. Nat Cell Biol 26(12):2099-2114 PMID: 39511379
- 7. Choudhury C et al.. 2025. Arylamine N-acetyltransferase 1 expression predicts glucose dependence and mitochondrial bioenergetics in cancer cells.. Biochim Biophys Acta Mol Cell Res 1872(4):119929 PMID: 40054776
- 8. Choudhury C et al.. 2022. Polymorphism in the human arylamine N-acetyltransferase 1 gene 3'-untranslated region determines polyadenylation signal usage.. Biochem Pharmacol 200:115020 PMID: 35358480
